T

Tempus

AI-driven platform for medical data insights

Scientific Solutions Intern

Summer 2026Updated
$35/hr+ Relocation Bonus
Internship
Master's, PhD
Chicago, IL, USA
HybridHybrid role; onsite 3 days per week in Chicago.
Data & AnalyticsData Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • Pursuing an Advanced degree (Masters/PhD, graduating in Spring 2027 or Winter 2026) in a Quantitative or Computational field.
  • Computer Science, Data Science, Bioinformatics, Biomedical Engineering, or a related technical field. We also welcome students in Information Science or Technical Communications who possess a strong minor or background in programming and data analysis.
  • We are seeking a candidate with technical literacy and experience coding in R, or Python, as they’ll need to understand the analytical tools they are documenting.
  • Candidate should be process-oriented and interested in workflow development.
  • Candidates should be interested in AI agents and possess a basic understanding to evaluate how an AI Agent "thinks" when it parses documentation.
  • Excellent written and verbal communication skills in a variety of settings and media.
  • Strong computer skills, including advanced knowledge of Google Suite and Gmail, preferred.
  • A self-starter with the ability to work independently as well as in collaboration with others in a fast-paced environment is critical. Be ready to fly the plane as you’re still building it!
Responsibilities
  • Apply skills and knowledge learned in the classroom to on-the-job experiences
  • Work on comprehensive, value-added project(s) that help enhance the fields of science and technology
  • Collaborate with teams/colleagues in a fast-paced environment
  • Gain professional development & build relationships with peers from across the country
  • Migrating client documentation to a more modern platform, learn to use Git, and develop programmatic workflows for documentation maintenance
  • Help enhance agentic workflows by testing and validating AI agents' responses to queries, ensuring they correctly utilize our extensive documentation.

About the company

Tempus provides an AI-powered platform that analyzes medical data and images to help physicians improve patient care and supports drug development for pharmaceutical and biotech companies. The platform produces actionable insights, finds gaps in care, and helps identify personalized therapy options for patients, while researchers use it for drug target discovery and evaluating treatments. It differentiates itself with a proprietary data-and-imaging platform paired with cancer-focused research tools, including a pan-cancer organoid platform and a validated liquid biopsy assay for profiling circulating tumor DNA. Its goal is to improve patient outcomes through data-driven, personalized medicine and to speed cancer research and development.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, IL

Founded

2015

Get referred to Tempus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus raised 2026 revenue guidance to $1.595 billion-$1.605 billion after Q2 momentum.
  • ARPA-H awarded Tempus up to $9.5 million for heart-failure AI on September 9, 2026.
  • Tempus launched a 100,000-genome dataset, with general availability targeted for mid-2027.

What critics are saying

  • Guardant Health's Delaware patent suits seek injunctions against xF and xM tests.
  • Farrier v. Tempus AI alleges genetic-data misuse under Illinois GIPA since February 2026.
  • Autonomous heart-failure AI needs FDA authorization within 24 months, exposing Tempus to regulatory failure.

What makes Tempus unique

  • Tempus pairs multimodal records, pathology, genomics, and longitudinal outcomes at scale.
  • Tempus earned four FDA-cleared ECG AI products by September 2026.
  • Leica Biosystems added Tempus Paige products to Aperio AI Store on September 24, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Relocation Assistance
  • Company Equity
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Nov 2nd, 2026
Tempus AI Q3 revenue up 23% to $411.5M, guidance raised to $1.6B

Tempus AI reported third-quarter revenue of $411.5 million, up 23% from a year earlier, and raised its 2026 revenue guidance to $1.60 billion to $1.605 billion. Adjusted EBITDA was $25.6 million, and the company ended the quarter with $854.4 million in cash and marketable securities. Diagnostics revenue rose 20% to $303.5 million, led by a 28% rise in oncology revenue. Data-and-applications revenue climbed 33% to $108.1 million. New data deals with Bristol Myers Squibb and Pathos are expected to add $192.5 million in revenue over roughly five years. Tempus also expects to expand its minimal residual disease testing after its planned acquisition of Personalis, though reimbursement and test profitability remain uncertain.

Health IT Answers
Oct 29th, 2026
Health IT business news, financial edition - october 29, 2026.

Health IT business news, financial edition - october 29, 2026. DirectTrust and GLEIF Partner on Verifiable Organizational Identity for Healthcare DirectTrust and the Global Legal Entity Identifier Foundation announced a partnership to develop a Qualification Agent model supporting adoption of verifiable Legal Entity Identifiers in U.S. healthcare. The initiative would enable qualified organizations to help establish and verify digital organizational identities, supporting trusted electronic transactions and healthcare information exchange. Vera Health Raises $32 Million for clinical AI search platform Vera Health announced a $28.5 million Series A led by Threshold Ventures, with participation from Mantis VC and SV Angel. Existing investors Y Combinator and Gradient tripled down, bringing the company's total funding to $32 million. The company will use the funds to expand its clinical AI platform and build partnerships with medical societies, publishers and health systems. Southwest General Expands its Partnership with Oracle Oracle announced that Southwest General Health Center in Ohio is expanding its technology relationship to include Oracle Health Patient Accounting, Oracle Health Data Intelligence and Oracle Fusion Cloud Applications. The expansion builds on Southwest General's existing Oracle Health electronic health record and AI documentation capabilities and will integrate clinical, revenue cycle, financial and operational information across the organization. The Springs Living and PointClickCare Announce Technology Co-Development Partnership The Springs Living and PointClickCare announced a strategic partnership to develop technology connecting senior living communities with healthcare services. The agreement will involve PointClickCare working with frontline teams at several Springs Living communities in Oregon to design, test and implement technology supporting resident care and staff workflows. Hackensack Meridian Health Commits $30M to Epic Implementation as Part of Hunterdon Health Merger Hackensack Meridian Health and Hunterdon Health announced a definitive agreement for Hunterdon Health to join the Hackensack Meridian network. As part of the proposed merger, Hackensack Meridian will invest $200 million in facilities, programs and expanded access to care, along with $30 million to implement the Epic electronic health record across Hunterdon Medical Center, ambulatory locations, affiliated practices and participating independent physicians. The transaction remains subject to regulatory approval. Mergers and acquisitions. Austco Healthcare to Acquire RTM Solutions and CareTech Systems Austco Healthcare announced agreements to acquire RTM Solutions, a provider of real-time monitoring and systems-integration software for healthcare facilities, and CareTech Systems, a developer of nurse call technology. Contract announcements. Pathos AI Signs $55M Data Agreement With Tempus AI, Expands Collaboration With Bristol Myers Squibb Pathos AI announced strategic collaborations with Bristol Myers Squibb and Tempus AI to advance AI-driven drug development for Alzheimer's disease and other neurological conditions. Under a five-year, $55 million agreement, Tempus will develop a de-identified longitudinal dataset covering hundreds of thousands of patients with neurological conditions for use by Pathos. Bristol Myers Squibb will gain access to Pathos' Foundry AI platform, including exclusive rights for neuroscience development programs over three years. St. Luke's Health System Selects hellocare.ai for Enterprise Virtual Care Deployment hellocare.ai announced that St. Luke's Health System selected its AI-assisted virtual care platform for deployment across hospitals and inpatient facilities in southern Idaho. The agreement includes virtual nursing, virtual patient observation, telehealth and AI-supported care coordination capabilities. PacBio and Verily Health Announce Multiyear Collaboration for Biomedical AI PacBio and Verily Health announced a multiyear strategic collaboration to integrate PacBio's HiFi sequencing technology with Verily's healthcare data and AI platform. The agreement will connect genomic sequencing workflows with clinical data to create datasets for biomedical research, AI model development and precision medicine applications. Healthcare Triangle Subsidiary Secures Multiyear Health IT Contracts Healthcare Triangle announced that its Purpose Health subsidiary signed several multiyear agreements, including a master services agreement with a university health system for electronic health record optimization and cybersecurity services. The company also secured an agreement to provide IT services supporting a healthcare business unit's global technology center and reported additional advisory work involving MEDITECH and rural health transformation initiatives. Oracle and AstraZeneca Announce AI Collaboration for Clinical Research Oracle and AstraZeneca announced a nonbinding agreement to explore applications of AI, cloud technology and real-world data in clinical research. The companies plan to evaluate tools for identifying clinical trial participants, improving evidence generation and connecting research insights with clinical workflows. Initial work will focus on hypertension care and clinical research in Abu Dhabi, with additional projects under consideration. Venture capitol and funding. Kivo Health Raises $10M in Series A At-home virtual care provider Kivo Health raised $10 million in Series A funding, to scale AI-powered care for seniors with chronic disease. Sunlight AI Raises $17.4M in Seed Funding to Support Independent Medical Practices Sunlight AI announced its launch and $17.4 million in seed funding to develop an AI-enabled operating platform for independent medical practices. The round was led by Lan Xuezhao, founder of Basis Set Ventures, with participation from Sofeon Ventures, Social Leverage, Actions Capital, Overlook Ventures and Early Light Ventures. The company also announced its acquisition of Bradford Medical Associates as part of its strategy to provide administrative, financial and operational support to independent physicians. XRlabs Raises $8.4M in Seed Funding for AI-Powered Surgical Platform XRlabs announced $8.4 million in seed funding led by Playground Global, with participation from Eka Ventures. The financing will support development and clinical deployment of the company's AI powered surgical platform, which combines live surgical video, navigation data and patient imaging to provide real-time information during procedures. XRlabs also announced that former Medtronic Chairman and CEO Omar Ishrak has joined its board as chair. Pathos AI Raises $237M Series E at $3B Valuation Pathos AI announced a $237 million Series E financing round led by Bristol Myers Squibb, with participation from existing investors. The round values the AI-driven drug development company at approximately $3 billion. The funding will support expansion of its Foundry AI platform and clinical development of its oncology pipeline. Baba Raises $40M Series A to Expand AI-Enabled Medicare Care Coordination Baba, an AI-enabled care coordination company serving Medicare and Medicaid populations, announced a $40 million Series A led by FirstMark Capital, with participation from CVS Health Ventures, Valtruis, General Catalyst, Genius Ventures and Ground Up Ventures. The funding will support expansion of the company's clinical care teams, AI research and partnerships with health plans, as well as its value-based care arrangements. Making the cut, milestones, accolades, awards and more. Hackensack Meridian Health Commits $30M to Epic Implementation as Part of Hunterdon Health Merger Hackensack Meridian Health and Hunterdon Health announced a definitive agreement for Hunterdon Health to join the Hackensack Meridian network. As part of the proposed merger, Hackensack Meridian will invest $200 million in facilities, programs and expanded access to care, along with $30 million to implement the Epic electronic health record across Hunterdon Medical Center, ambulatory locations, affiliated practices and participating independent physicians. The transaction remains subject to regulatory approval.

MarketScreener
Oct 23rd, 2026
Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research.

Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research. Pathos AI announced a partnership with Bristol Myers Squibb and Tempus AI to harness artificial intelligence in the development of treatments for Alzheimer's disease and other neurological disorders. The collaboration comes with a $237m Series E funding round led by Bristol Myers Squibb, valuing the New York-based company at approximately $3bn. The transaction aims to strengthen Pathos AI's research capabilities and accelerate the identification of new therapeutic avenues through the analysis of large-scale medical data. Published on 10/23/2026 at 10:57 am EDT MarketScreener.com Under the agreement, Tempus AI will build a database covering several hundred thousand patients with neurological diseases, which Pathos AI will be able to access for five years in exchange for $55m. The information will be analyzed by its Pathos Foundry platform to gain a better understanding of the biological mechanisms behind diseases, identify potential treatments and improve the design of clinical trials. Bristol Myers Squibb will receive strategic, nonexclusive access to the technology across all of its research and development activities, as well as exclusive rights for three years to its neuroscience programs. The $237m raised will also enable Pathos AI to develop its platform and advance its pipeline of experimental drugs. The projects involved include JSKN016, an experimental cancer treatment, as well as a breast cancer program being conducted with AstraZeneca. The strategy reflects the company's intention to expand the use of artificial intelligence beyond neurological diseases, particularly in oncology. For the three partners, the goal is to make better use of medical data to accelerate drug discovery and make clinical trials more precise and better suited to patients. (C) MarketScreener.com - 2026

MarketScreener
Oct 23rd, 2026
Tempus AI expands Bristol Myers partnership with multi-year oncology, AI data deals.

Tempus AI expands Bristol Myers partnership with multi-year oncology, AI data deals. Published on 10/23/2026 at 10:32 am EDT - Modified on 10/23/2026 at 10:37 am EDT By Adriano Marchese Tempus AI signed a multi-year deal with Bristol Myers Squibb to license oncological data and provide access to its artificial intelligence-powered platform. Under the terms of the deal, Bristol Myers will gain access to Tempus's Lens Platform, the company's agentic AI platform for oncology drug development, which is built on real-world multimodal datasets. The agreement will run through 2031 to support biological and clinical insight, novel drug target discovery and therapeutic development across the pharmaceutical company's oncology portfolio. Additionally, clinical-stage technology firm Pathos AI is also broadening its strategic collaborations with both Bristol Myers and Tempus AI. The collaboration aims to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. Bristol Myers led a $237 million Series E financing round for Pathos at a $3 billion valuation, gaining rights to Pathos' Foundry AI platform and broader portfolio. According to a regulatory filing on Friday, the combined agreements provide Tempus with $192.5 million in total cash commitments over five years, consisting of $137.5 million directly from Bristol Myers, and $55 million from Pathos AI for 500,000 de-identified patient records. Write to Adriano Marchese at [email protected] (END) Dow Jones Newswires 10-23-26 1031ET (C) Dow Jones - 2026

941 The Duke
Oct 23rd, 2026
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development.

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development. By Thomson Reuters Oct 23, 2026 | 9:00 AM Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors. Here are some other details: - Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology - Pathos will license the data from Tempus under a five-year, $55 million agreement - Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials - Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs - Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016 - The funding will help advance development of other cancer programs including an AstraZeneca-partnered experimental breast cancer drug (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)

INACTIVE